BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 10, 2026
Home » Money raised by biotech: 2019 vs. 2018

Money raised by biotech: 2019 vs. 2018

Aug. 1, 2019

Article reprints

To read more on related topics, click on one of the words below.

BioWorld

    • Related Articles

      Money raised by biotech: 2019 vs. 2018

      Money raised by biotech, 2019 vs. 2018

      Money raised by biotech: 2019 vs. 2018

    Popular Stories

    • Today's news in brief

      BioWorld
      BioWorld briefs for March 9, 2026.
    • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

      Cas and effect: Merck’s phase III ripples HIF-2α space

      BioWorld
      Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
    • Tanycytes in green capturing tau protein in red.

      Brain’s hidden tau-clearing pathway uncovered

      BioWorld Science
      Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

    • News in brief

      BioWorld Asia
      BioWorld Asia briefs for March 3, 2026

    • MSD synthesizes α-synuclein PET agents

      BioWorld Science
      Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
    • BioWorld
      • Today's news
      • Analysis and data insight
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Medical technology
      • Newco news
      • Opinion
      • Regulatory
    • BioWorld Science
      • Today's news
      • Biomarkers
      • Cancer
      • Conferences
      • Endocrine/metabolic
      • Immune
      • Infection
      • Neurology/psychiatric
      • NME Digest
      • Patents
    • BioWorld Asia
      • Today's news
      • Analysis and data insight
      • Australia
      • China
      • Clinical
      • Deals and M&A
      • Financings
      • Newco news
      • Regulatory
      • Science
    • More
      • About
      • Advertise with BioWorld
      • Archives
      • Article reprints and permissions
      • Contact us
      • Cookie policy
      • Copyright notice
      • Data methodology
      • Infographics: Dynamic digital data analysis
      • Index insights
      • Podcasts
      • Privacy policy
      • Share your news with BioWorld
      • Staff
      • Terms of use
      • Topic alerts
    Follow Us

    Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing